# US 2022/0033494 A1 · Anti-l1cam antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033494 A1
- Document ID: US20220033494A1
- Status: Published application
- Kind: A1
- Application number: 17/250,286
- Filed: 2019-06-27
- Published: 2022-02-03
- Earliest claimed: 2018-06-29
- Assignees: ApitBio, Inc
- Applicants: ApitBio, Inc
- Inventors: Hyo Jeong HONG; Heesu CHAE; Jisu HONG
- Web page: https://patentgrep.com/patent/US20220033494A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- G01N 33/5751: of the skin, e.g. melanoma
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- A61K 2039/585: {wherein the target is cancer}
- C07K 2317/31: multispecific
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides antibodies that specifically bind to L1CAM and compositions comprising such antibodies. Also provided herein are methods for preventing or treating diseases or conditions which comprise a tumor using the anti-L1CAM antibodies.

## Claims

### Claim 1

An isolated antibody or antigen-binding fragment thereof that specifically binds to the same L1 Cell Adhesion Molecule (L1CAM), wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) complementarity determining region 1 (CDR1), CDR2, and CDR3 and a light chain variable region (VL) CDR1, CDR2, and CDR3;
(i) wherein the VH CDR1, CDR2, and CDR3 comprises RFGMH (SEQ ID NO: 2), FISNEGSNKYYADSVKG (SEQ ID NO: 10), and GRAYGSGSLFDP (SEQ ID NO: 4), respectively; and wherein the VL CDR1, CDR2, and CDR3 comprises RASRTISSYVN (SEQ ID NO: 12), AASNLHS (SEQ ID NO: 7), and QQSIGRGPVT (SEQ ID NO: 13), respectively;
(ii) wherein the VH CDR1, CDR2, and CDR3 comprises RFGMH (SEQ ID NO: 2), FISNEGSNKYYADSVKG (SEQ ID NO: 10), and GRAYGSGSLFDP (SEQ ID NO: 4), respectively; and wherein the VL CDR1, CDR2, and CDR3 comprises RASRTISSYVN (SEQ ID NO: 12), AASNLHS (SEQ ID NO: 7), and QQAGFYSPWT (SEQ ID NO: 17), respectively;
(iii) wherein the VH CDR1, CDR2, and CDR3 comprises RFGMH (SEQ ID NO: 2), FISNEGSNKYYADSVKG (SEQ ID NO: 10), and GRAYGSGSLFDP (SEQ ID NO: 4), respectively; and wherein the VL CDR1, CDR2, and CDR3 comprises RASRTISSYVN (SEQ ID NO: 12), AASNLHS (SEQ ID NO: 7), and QQAGFYTPWT (SEQ ID NO: 15), respectively;
(iv) wherein the VH CDR1, CDR2, and CDR3 comprises RFGMH (SEQ ID NO: 2), FISNEGSNKYYADSVKG (SEQ ID NO: 10), and GRAYGSGSLFDP (SEQ ID NO: 4), respectively; and wherein the VL CDR1, CDR2, and CDR3 comprises RASRTISSYVN (SEQ ID NO: 12), AASNLHS (SEQ ID NO: 7), and QQSLHFYPWT (SEQ ID NO: 19), respectively; or
(v) wherein the VH CDR1, CDR2, and CDR3 comprises RFGMH (SEQ ID NO: 2), FISNEGSNKYYADSVKG (SEQ ID NO: 10), and GRAYGSGSLFDP (SEQ ID NO: 4), respectively; and wherein the VL CDR1, CDR2, and CDR3 comprises RASRTISSYVN (SEQ ID NO: 12), AASNLHS (SEQ ID NO: 7), and QQSLVWYPWT (SEQ ID NO: 21), respectively.

### Claim at position 2

2-17. (canceled)

### Claim 18 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3, wherein the light CDR1 comprises RASRTISSYVN (SEQ ID NO: 12), the light chain CDR2 comprises AASNLHS (SEQ ID NO: 7), the light chain CDR3 comprises QQSIGRGPVT (SEQ ID NO:13), the heavy chain CDR1 comprises RFGMH (SEQ ID NO: 2), the heavy chain CDR2 comprises FISNEGSNKYYADSVKG (SEQ ID NO: 10), and the heavy chain CDR3 comprises GRAYGSGSLFDP (SEQ ID NO: 4).

### Claim at position 4

19-22. (canceled)

### Claim 23 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof has one or more characteristics:
(a) the antibody or antigen-binding fragment thereof exhibits improved productivity;
(b) the antibody or antigen-binding fragment thereof exhibits improved affinity as measured by the equilibrium dissociation constant (KD);
(c) the antibody or antigen-binding fragment thereof exhibits improved PI value,
(d) the antibody or antigen-binding fragment thereof exhibits improved affinity as measured by the association constant (K); or
(e) any combination thereof.

### Claim 24

(canceled)

### Claim 25 (depends on 23)

The antibody or antigen-binding fragment thereof of claim 23, wherein the improved productivity is at least 55 mg/L, at least 56 mg/L, at least 57 mg/L, at least 58 mg/L, at least 59 mg/L, at least about 60 mg/L, at least about 61 mg/L, at least about 62 mg/L, at least about 63 mg/L, at least about 64 mg/L, at least about 65 mg/L, at least about 66 mg/L, at least about 67 mg/L, at least about 68 mg/L, at least about 69 mg/L, at least about 70 mg/L, at least about 71 mg/L, at least about 72 mg/L, at least about 73 mg/L, at least about 74 mg/L, at least about 75 mg/L, at least about 76 mg/L, at least about 77 mg/L, at least about 78 mg/L, at least about 79 mg/L, at least about 80 mg/L, at least about 81 mg/L, at least about 82 mg/L, at least about 83 mg/L, at least about 84 mg/L, or at least about 85 mg/L, when expressed according to example 3;
wherein the improved KD is less than 2.6×10−10 M, less than 2.5×10−10 M, less than 2.0×10−10 M, less than 1.5×10−10 M, less than 1.0×10−10 M, less than 9×10−11M, less than 8×10−11M, less than 7×10−11M, less than 6×10−11M, less than 5×10−11M, less than 4×10−11M, less than 3×10−11M, less than 2×10−11M, less than 1×10−11M, less than 9×10−12M, less than 8×10−12M, less than 7×10−12M, less than 6×10−12 M, less than 5×10−12M, less than 4×10−12M, less than 3×10−12M, less than 2×10−12M, less than 1×10−12M, less than 9×10−13M, or less than 8×10−13 M;
wherein the improved affinity (K) is less than 5×10−10 M, less than 4×10−10 M, less than 3×10−10 M, less than 2×10−10 M, less than 1.0×10−10 M, less than 9×10−11M, less than 8×10−11M, less than 7×10−11 M, less than 6×10−11 M, less than 5×10−11 M, less than 4×10−11M, less than 3×10−11 M, less than 2×10−11 M, less than 1×10−11 M, less than 9×10−12 M, less than 8×10−12 M, less than 7×10−12M, less than 6×10−12 M, less than 5×10−12M, less than 4×10−12 M, less than 3×10−12 M, less than 2×10−12 M, less than 1×10−12 M, less than 9×10−13 M, or less than 8×10−13 M; and/or
wherein the improved PI Value is less than 9.6, less than 9.5, less than 9.4, less than 9.3, less than 9.2, less than 9.1, less than 9.0, less than 8.9, less than 8.8, less than 8.7, less than 8.6, less than 8.5, less than 8.4, less than 8.3, less than 8.2, less than 8.1, less than 8.0, less than 7.9, less than 7.8, less than 7.7, or less than 7.6.

### Claim at position 8

26-36. (canceled)

### Claim 37 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the VH comprises an amino acid sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth as EVQLVESGGGVVQPGGSLRLSCAASGFTFSRFGMHWVRQAPGKGLEWVAFSNEGSNKYYADSVKGRFTSRDNSANTLY LQMNSLRAEDTAVYYCARGRAYGSGSLFDPWGQGTLVTVSS(SEQ ID NO: 23) and wherein the VL, comprises an amino acid sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth as
(SEQ ID NO: 24)
DIQLTQSPSSLSASVGDRVTITCRASRTISSYVNWYRQRPGKAPESLIY
AASNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSIGRGPVT
FGQGTKLEIK;
wherein the VH comprises an amino acid sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth as EVQLVESGGGVVQPGGSLRLSCAASGFTFSRFGMHWVRQAPGKGLEWVAFSNEGSNKYYADSVKGRFTSRDNSANTLY LQMNSLRAEDTAVYYCARGRAYGSGSLFDPWGQGTLVTVSS (SEQ ID NO: 27) and wherein the VL comprises an amino acid sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth as
(SEQ ID NO: 28)
DIQLTQSPSSLSASVGDRVTITCRASRTISSYVNWYRQRPGKAPESLIY
AASNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAGFYSPWT
FGQGTKLEIK;
wherein the VH comprises an amino acid sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth as EVQLVESGGGVVQPGGSLRLSCAASGFTFSRFGMHWVRQAPGKGLEWVAFISNEGSNKYYADSVKGRFTISRDNSANTLY LQMNSLRAEDTAVYYCARGRAYGSGSLFDPWGQGTLVTVSS (SEQ ID NO: 25) and wherein the VL comprises an amino acid sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth as
(SEQ ID NO: 26)
DIQLTQSPSSLSASVGDRVTITCRASRTISSYVNWYRQRPGKAPESLIY
AASNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAGFYTPWT
FGQGTKLEIK;
wherein the VH comprises an amino acid sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth as EVQLVESGGGVVQPGGSLRLSCAASGFTFSRFGMHWVRQAPGKGLEWVAFISNEGSNKYYADSVKGRFTISRDNSANTLY LQMNSLRAEDTAVYYCARGRAYGSGSLFDPWGQGTLVTVSS (SEQ ID NO: 29) and wherein the VL comprises an amino acid sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth as
(SEQ ID NO: 30)
DIQLTQSPSSLSASVGDRVTITCRASRTISSYVNWYRQRPGKAPESLIY
AASNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSLHFYPWT
FGQGTKLEIK;
or
wherein the VH comprises an amino acid sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth as EVQLVESGGGVVQPGGSLRLSCAASGFTFSRFGMHWVRQAPGKGLEWVAFSNEGSNKYYADSVKGRFTSRDNSANTLY LQMNSLRAEDTAVYYCARGRAYGSGSLFDPWGQGTLVTVSS (SEQ ID NO: 31) and wherein the VL comprises an amino acid sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence set forth as
(SEQ ID NO: 32)
DIQLTQSPSSLSASVGDRVTITCRASRTISSYVNWYRQRPGKAPESLIY
AASNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSLVWYPWT
FGQGTKLEIK.

### Claim at position 10

38-59. (canceled)

### Claim 60 (depends on 1)

A nucleic acid encoding the antibody or antigen-binding fragment thereof of claim 1.

### Claim 61 (depends on 60)

A vector comprising the nucleic acid of claim 60.

### Claim 62 (depends on 61)

A host cell comprising the vector of claim 61.

### Claim 63

(canceled)

### Claim 64 (depends on 1)

An immunoconjugate comprising the antibody or antigen-binding fragment thereof of claim 1, linked to an agent.

### Claim 65 (depends on 1)

A bispecific or multispecific antibody comprising the antibody or antigen-binding fragment thereof of claim 1, and an antibody or antigen-binding fragment thereof that binds to an antigen.

### Claim 66 (depends on 1)

A composition comprising the antibody or antigen-binding fragment thereof of claim 1, and a carrier.

### Claim 67 (depends on 1)

A kit comprising the antibody or antigen-binding fragment thereof of claim 1.

### Claim 68 (depends on 60)

An immune cell comprising the nucleic acid of claim 60.

### Claim 69 (depends on 68)

The immune cell of claim 68, which is a T cell or an NK cell.

### Claim 70 (depends on 1)

An immune cell, which comprises a chimeric antigen receptor comprising the antibody or antigen-binding fragment thereof of claim 1.

### Claim 71 (depends on 62)

A method of producing an antibody or an antigen-binding fragment thereof which specifically binds to a human L1CAM protein, comprising culturing the cell of claim 62 under suitable conditions and isolating the antibody.

### Claim 72 (depends on 1)

A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject the antibody or antigen-binding fragment thereof of claim 1, wherein the disease or condition comprises a tumor.

### Claim at position 24

73-77. (canceled)

### Claim 78 (depends on 72)

The method of claim 72, comprising administering an additional therapeutic agent.

### Claim at position 26

79-80. (canceled)

### Claim 81

An antibody or antigen-binding fragment thereof specifically binding to L1 CAM, wherein the antibody or antigen-binding fragment thereof comprises a VH and a VL, wherein the VH of the antibody or antigen-binding fragment thereof comprises SEQ ID NO: 23 and the VL of the antibody or antigen-binding fragment thereof comprises SEQ ID NO: 24.

### Claim 82 (depends on 37)

The antibody or antigen-binding fragment thereof of claim 37, wherein the antibody or antigen-binding fragment thereof further comprises a heavy chain (HC) constant region and a light chain (LC) constant region, wherein the HC constant region comprises amino acids 122 to 451 of SEQ ID NO: 38 and the LC constant region comprises amino acids 109 to 215 of SEQ ID NO: 39.
